FREQUENCY OF DERANGED LIPID PROFILE IN PATIENTS ON OLANZAPINE

Abstract

This study aims to determine how often patients develop abnormal lipid levels while taking Olanzapine.

Users of Olanzapine, an atypical antipsychotic drug, typically receive this medication for schizophrenia management and treatment of bipolar disorder. The use of this medication leads to metabolic side effects that induce dyslipidemia, which presents a growth in heart disease risk for patients. Early diagnosis and medical care for patients taking Olanzapine requires understanding the occurrence rates of lipid abnormalities.

Research with 189 participants studied olanzapine patients from Khyber Teaching Hospital in Peshawar, Pakistan. The research investigators selected non-probability consecutive sampling to obtain their data. Researchers obtained information about participant characteristics, their medical features, and laboratory findings, including total cholesterol testing and measurements of triglycerides and LDL and HDL levels. The statistical evaluation involved IBM SPSS version 24, in which researchers assessed variable relationships through mean calculations paired with frequency distribution and Chi-Square statistical approaches.

The examination of 120 patients revealed deranged lipid profiles in 65.6% of studied patients on olanzapine therapy with triglycerides elevated in 37.5%. At the same time, total cholesterol increased by 28.6%, and HDL levels were reduced among 22.2% of subjects. Statistical analysis findingsStatistical analysis findings showed that prolonged olanzapine administration resulted in detectable lipid disorder patterns (p < 0.05).

The research shows that common lipid abnormalities occur frequently among patients taking Olanzapine, so healthcare providers must conduct regular lipid level assessments followed by appropriate risk reduction strategies for cardiovascular health.